GP2013 + chemotherapy

GP2013 + chemotherapy is a combination therapy consisting of GP2013, a biosimilar to rituximab, together with a standard chemotherapy regimen. GP2013 is a monoclonal antibody that targets the CD20 protein on B lymphocytes, contributing to the destruction of malignant lymphoma cells. The chemotherapy typically given in this combination is CVP (cyclophosphamide, vincristine, and prednisolone/prednisone), which has cytotoxic effects on dividing cancer cells. This regimen has been investigated as a first-line treatment for follicular lymphoma, aiming to compare its efficacy and safety to rituximab plus chemotherapy[1][2][3][4][5].